Share This Article:

Bowel Perforation Following Continuation of Bevacizumab Post Nasal Septal Perforation―A Case Report

Abstract Full-Text HTML XML Download Download as PDF (Size:234KB) PP. 319-321
DOI: 10.4236/crcm.2014.35070    2,813 Downloads   3,626 Views  

ABSTRACT

We report the case of a 63-year-old male with an inoperableT4N1 adenocarcinoma of colon, K-RAS mutant, who received first line chemotherapy with capecitabine and oxaliplatin. A CT scan following 4 cycles demonstrated progressive disease, and second line therapy with capecitabine, irinotecan and bevacizumab was commenced. CT scans at 3 and 6 months during this treatment regime demonstrated radiologically stable disease, and therefore the treatment was continued. The patient developed nasal septal perforation, a rare but recognised complication of bevacizumab therapy, which was managed conservatively. Here we highlight that no consensus exists on whether bevacizumab should be continued in this situation. After a detailed discussion about the risks and benefits, this patient continued on with the same therapeutic regime. However, eight weeks later, this patient then developed a localised tumour perforation, necessitating an emergency admission to his local hospital. We recommend caution in continuing bevacizumab in patients with colorectal cancer following a nasal septal perforation and advise a detailed discussion of risk with the patient, especially when the primary tumour remains in-situ.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Nelmes, D. and Gwynne, S. (2014) Bowel Perforation Following Continuation of Bevacizumab Post Nasal Septal Perforation―A Case Report. Case Reports in Clinical Medicine, 3, 319-321. doi: 10.4236/crcm.2014.35070.

References

[1] Ellis, L.M. (2006) Mechanisms of Action of Bevacizumab as a Component of Therapy for Metastatic Colorectal Cancer. Seminars in Oncology, 33, S1-S7.
[2] Whyte, S., Pandor, A. and Stevenson, M. (2012) Bevacizumab for Metastatic Colorectal Cancer: A NICE Single Technology Appraisal. Pharmacoeconomics, 30, 1119-1132.
http://dx.doi.org/10.2165/11597210-000000000-00000
[3] Mailliez, A., et al. (2010) Nasal Septum Perforation: A Side Effect of Bevacizumab Chemotherapy in Breast Cancer Patients. British Journal of Cancer, 103, 772-775.
http://dx.doi.org/10.1038/sj.bjc.6605828
[4] Ramiscal, J.A. and Jatoi, A. (2011) Bevacizumab-Induced Nasal Septal Perforation: Incidence of Symptomatic, Confirmed Event(s) in Colorectal Cancer Patients. Acta Oncologica, 50, 578-581.
http://dx.doi.org/10.3109/0284186X.2010.537692
[5] Mailliez, A., et al. (2010) Nasal Septum Perforations: A Side Effect of the Association of Bevacizumab and Taxanes in Patients with Breast Cancer? ASCO Meeting Abstracts, 28, 671.
[6] Hapani, S., Chu, D. and Wu, S. (2009) Risk of Gastrointestinal Perforation in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis. The Lancet Oncology, 10, 559-568.
http://dx.doi.org/10.1016/S1470-2045(09)70112-3
[7] Hompes, D. and Ruers, T. (2011) Review: Incidence and Clinical Significance of Bevacizumab-Related Non-Surgical and Surgical Serious Adverse Events in Metastatic Colorectal Cancer. European Journal of Surgical Oncology (EJSO), 37, 737-746.
http://dx.doi.org/10.1016/j.ejso.2011.06.004
[8] Van Cutsem, E., et al. (2009) Safety and Efficacy of First-Line Bevacizumab with FOLFOX, XELOX, FOLFIRI and Fluoropyrimidines in Metastatic Colorectal Cancer: The BEAT Study. Annals of Oncology, 20, 1842-1847.
http://dx.doi.org/10.1093/annonc/mdp233
[9] Kozloff, M., et al. (2009) Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. The Oncologist, 14, 862-870.
http://dx.doi.org/10.1634/theoncologist.2009-0071
[10] Poultsides, G.A., et al. (2009) Outcome of Primary Tumor in Patients with Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy without Surgery as Initial Treatment. Journal of Clinical Oncology, 27, 3379-3384. http://dx.doi.org/10.1200/JCO.2008.20.9817

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.